Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(R)-1,3-butanediol is a chiral secondary alcohol with two hydroxyl groups (diol) that serves as an endogenous metabolite and research compound[3][8]. The (R)-enantiomer undergoes stereospecific metabolism to β-hydroxybutyrate via alcohol dehydrogenase through zinc-dependent pathways, maintaining cellular redox balance[3]. It has been investigated for its potential to regulate carbohydrate and lipid metabolism[4] and induce mild euphoric effects through ketone body signaling pathways distinct from ethanol's GABAergic mechanisms[3]. The compound is colorless, odorless, and water-soluble with a slightly sweet taste and bitter aftertaste[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (R)-1,3-butanediol.